St. Louis-based biotech startup C2N Diagnostics snags $2.2M in funding to advance Alzheimer's blood test
September 24, 2020 at 07:59 AM EDT
The Alzheimer’s Drug Discovery Foundation, based in New York, said the funding is targeted toward advancing clinical validation and deployment of C2N’s PrecivityAD blood test for Alzheimer’s disease.
